News | August 29, 2025
Sai Life Sciences completes Phase II of production block 11 at Bidar
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Subscribe To Our Newsletter & Stay Updated
